Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Pretty weak financial results growth rate 6.9% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-4.1%)
  • Dividend yield for the last twelve months 1.7%
  • Free cash flow yield -2.9% (LTM)
  • Share price is 46.9% higher than minimum and 5.5% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (30.1x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $77.9 mln (-0.034% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (-0.1%)132.49
year average price 114.61  


year start price 112.02 2024-04-02

min close price 100.07 2024-07-18

max close price 140.22 2025-03-03

current price 132.49 2025-04-01
Common stocks: 1 746 881 140

Dividend Yield:  1.7%
FCF Yield LTM: -2.9%
EV / LTM EBITDA: 30.1x
EV / EBITDA annualized: 27.3x
Last revenue growth (y/y):  +7.2%
Last growth of EBITDA (y/y):  +6.7%
Historical revenue growth:  -0.4%
Historical growth of EBITDA:  -7.7%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 231 444
Net Debt ($m): 14 375
EV (Enterprise Value): 245 819
EBITDA LTM ($m): 8 165
EV / LTM EBITDA: 30.1x
Price to Book: 5.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-04-01zacks.com

ABT Stock to Gain From Early CE Mark Approval of Volt PFA System

2025-03-31zacks.com

Abbott (ABT) Outperforms Broader Market: What You Need to Know

2025-03-24zacks.com

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

2025-03-17zacks.com

Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?

2025-03-17seekingalpha.com

Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees

2025-03-07fool.com

2 Dependable Dividend Stocks That Can Pay You for Life

2025-03-07fxempire.com

Strong Earnings Lift Abbott Laboratories Shares

2025-03-04businesswire.com

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

2025-02-21prnewswire.com

Abbott Declares 405th Consecutive Quarterly Dividend

2025-02-20zacks.com

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data